A Sampling of Clinical Data and Supporting Evidence
The Ceribell EEG system has been clinically validated across 80+ publications and abstracts, including reports on 2 multi-center trials
Impact on Clinical Management
SAFER-EEG TRIAL: Shorter median ICU length of stays with Ceribell and more patients from the Ceribell cohort with better neurological outcomes compared to conventional EEG1
- 4.1-day shorter median ICU length of stay with Ceribell vs. convEEG
- 18% more patients from the Ceribell cohort had better neurological outcomes***
- 19.4 hours faster door-to-EEG time
SAFER-EEG TRIAL: Performance of the 2HELPS2B score with Ceribell is comparable to conventional EEG for forecasting seizure risk in acutely ill patients2
- Comparable 72 hours in-hospital seizure risk forecasting with Ceribell vs. conventional EEG
- If Ceribell 2HELPS2B=0, the risk of seizures in the next 24h is only ~2%
Ceribell use in the ED has the potential to positively impact the clinical management of suspected non-convulsive seizures3
This prospective study conducted at two ED sites evaluated rapid EEG impact on seizure management when used by emergency physicians. Ceribell changed clinical management for 53% of patients.
- Ceribell expedited disposition of 21% of patients
- ED physicians identified seizures with 100% sensitivity and 92% specificity when using Brain Stethoscope
DECIDE TRIAL: Ceribell Point-of-Care EEG was demonstrated to significantly improve clinical accuracy and confidence4
The DECIDE trial was a prospective, multi-center observational study that evaluated the clinical impact of Point-of-Care EEG. The device was set up by neurology residents and fellows without prior experience with Ceribell EEG. The qualitative results came from evaluations in user surveys.
Clarity Performance
Ceribell with Clarity offers 24/7 EEG monitoring with consistently high performance for detecting non-convulsive status epilepticus5,6
Retrospective assessment of clinical Ceribell EEGs across 11 centers evaluated the performance of Clarity to epileptologist consensus in generating bedside alerts for possible status epilepticus.
- 95% Sensitivity for alerting to suspected status epilepticus*
- 97% Specificity for ruling out status epilepticus*
- 99% NPV for ruling out seizure and status epilepticus**
*At ≥ 90% seizure burden
**At 0% seizure burden
Health Economics
Ceribell EEG is Associated with Improved Patient Care and Increased Reimbursement7
Retrospective 6-month review after POC EEG QI protocol implementation, compared to 6 months prior to POC EEG acquisition.
- 3-day trend of shorter median LOS, resulting in ~$4,850 average cost savings per patient
- 13% of Ceribell patients qualifying for seizure-associated CC or MCC reimbursement, leading to ~$7,300 average additional payment
Ceribell Point-of-Care EEG has the potential to alter the treatment course for patients with suspected seizures and may result in cost savings per patient8
This study built a two-armed cost–benefit model comparing decisions based on rapid EEG results with those based on clinical suspicion alone, using data from DECIDE, to examine the potential effect of Ceribell on hospital costs.
- Rapid EEG savings were $5,633 per use case (95% PI: $4,649 to $6,617)
- Cost savings were demonstrated in 75% of replications
- 64% of variance in total costs was attributable to LOS for patients incorrectly diagnosed with seizures
Optimal Number of Electrodes
Signal Quality
Ceribell EEG offers equivalent signal quality to conventional EEG11
Ceribell was compared to Natus and Nihon Kohden in three-way simultaneous recordings and demonstrated equivalence. Ceribell was also compared to conventional systems in consecutive recordings, demonstrating equivalence for all quality metrics apart from noise, where Ceribell had significantly lower 60 Hz noise.
Resources
Resource
Publication
DECIDE Study Assessing The Impact of Ceribell EEG – Manuscript Review With Dr. Paul Vespa
Watch Our WebinarWebinar